Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
139 hedge funds and large institutions have $1.17B invested in Avidity Biosciences in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 78 increasing their positions, 25 reducing their positions, and 23 closing their positions.
1,483% more call options, than puts
Call options by funds: $2.85M | Put options by funds: $180K
212% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.55% less ownership
Funds ownership: 107.76% → 107.21% (-0.55%)
6% less funds holding
Funds holding: 148 → 139 (-9)
26% less capital invested
Capital invested by funds: $1.57B → $1.17B (-$404M)
35% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$21.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$17.8M |
| 3 |
RI
RTW Investments
New York
|
+$17.2M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$13.3M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$44.2M |
| 2 |
Millennium Management
New York
|
-$16.7M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$10.2M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.88M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.66M |
RNAM Hedge Fund Activity: Q1 2023 in Review
139 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q1 2023, worth a combined $1.17B — down 26% from $1.57B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of RNAM and 15 opened new positions — a net loss of 8 holders — while 25 trimmed existing stakes and 78 added.
The largest buyer was RA Capital Management, adding an estimated $21.2M. The largest seller was Avidity Partners Management, cutting an estimated $44.2M.
- 139 institutional investors held Avidity Biosciences (RNAM) as of Q1 2023, down from 148 in Q4 2022.
- Funds reported $1.17B of Avidity Biosciences stock for Q1 2023, down 26% quarter-over-quarter.
- 15 funds opened new Avidity Biosciences positions in Q1 2023 and 23 closed out, a net change of -8 holders.
- The largest Avidity Biosciences buyer in Q1 2023 was RA Capital Management, an estimated $21.2M added.
- The largest Avidity Biosciences seller in Q1 2023 was Avidity Partners Management, an estimated $44.2M sold.
Based on aggregated 13F filings for Q1 2023.